Article(id=1330225309212849073, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225302346773381, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.04.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1643299200000, receivedDateStr=2022-01-28, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080028106, onlineDateStr=2026-11-19, pubDate=1649520000000, pubDateStr=2022-04-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080028106, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080028106, creator=13701087609, updateTime=1795080028106, updator=13701087609, issue=Issue{id=1330225302346773381, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='4', pageStart='347', pageEnd='484', issueExtLink='null', onlineDate='null', pubDate='1649520000000', pubDateStr='2022-04-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080026470, creator='13701087609', updateTime=1795084707533, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330244936621994666, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225302346773381, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330244936621994667, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225302346773381, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=377, endPage=385, ext={EN=ArticleExt(id=1330225309409981362, articleId=1330225309212849073, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=A new approach to chimeric antigen receptor T cell products health technology assessment, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Chimeric antigen receptor T cell (CAR-T) is a novel cancer immunotherapy. In order to solve two major difficulties of CAR-T health technology assessment (insufficient clinical evidence and high treatment cost), this paper proposed optimization ideas for health technology assessment on the basis of analyzing and learning international experience, including optimizing the selection of reference, optimizing assessment scheme and calculating budget impact precisely.

, authors=Yiman FENG1, Jinxi DING1, 2, *, Jiaming LI1, 2, Wei LI1, 2, authorsList=Yiman FENG, Jinxi DING, Jiaming LI, Wei LI, authorCompany=null, correspAuthors=Jinxi DING, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225309699388339, articleId=1330225309212849073, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=嵌合抗原受体T细胞产品卫生技术评估新思路, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)是一种全新的肿瘤免疫治疗产品。针对CAR-T产品卫生技术评估面临的两个难点,即临床证据不足和治疗费用昂贵,该文在分析借鉴国际经验基础上,提出卫生技术评估的优化思路,包括优选参照方案、优化评估方案和精算预算影响,以期为CAR-T产品卫生技术评估提供新思路。

, authors=冯依曼1, 丁锦希1, 2, *, 李佳明1, 2, 李伟1, 2, authorsList=冯依曼, 丁锦希, 李佳明, 李伟, authorCompany=null, correspAuthors=丁锦希, authorNote=

冯依曼,硕士研究生,研究方向:药物经济学和医保准入。

, correspAuthorsNote=
丁锦希,教授,博士生导师,研究方向:医药政策法规、医药市场准入与药物经济学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=rzLxETJ4qZOztCPp6d2Q1w==, magXml=Clp9V+V1VI4AWAcCUEESZQ==, pdfUrl=null, pdf=fYkUGvSvrq+lOjRimZYeUw==, pdfFileSize=1723456, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=VLWjzztgsQLUN6RD3q1Ugw==, mapNumber=null, fund=null)}, authors=[Author(id=1330225310215287739, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225310299173821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310215287739, language=EN, stringName=Yiman FENG, firstName=Yiman, middleName=null, lastName=FENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310362088382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310215287739, language=CN, stringName=冯依曼, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国药科大学国际医药商学院,江苏 南京 211198, bio={"content":"

冯依曼,硕士研究生,研究方向:药物经济学和医保准入。

"}, bioImg=null, bioContent=

冯依曼,硕士研究生,研究方向:药物经济学和医保准入。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)])]), Author(id=1330225310433391553, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225310504694724, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310433391553, language=EN, stringName=Jinxi DING, firstName=Jinxi, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310571803589, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310433391553, language=CN, stringName=丁锦希, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.中国药科大学国际医药商学院,江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])]), Author(id=1330225310655689671, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225310718604234, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310655689671, language=EN, stringName=Jiaming LI, firstName=Jiaming, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310777324491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310655689671, language=CN, stringName=李佳明, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国药科大学国际医药商学院,江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])]), Author(id=1330225310857016269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225310932513744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310857016269, language=EN, stringName=Wei LI, firstName=Wei, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310987039697, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310857016269, language=CN, stringName=李伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国药科大学国际医药商学院,江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])])], keywords=[Keyword(id=1330225311079314386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, language=EN, orderNo=1, keyword=chimeric antigen receptor T cell (CAR-T)), Keyword(id=1330225311146423251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, language=EN, orderNo=2, keyword=health technology assessment), Keyword(id=1330225311209337812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, language=EN, orderNo=3, keyword=medical insurance access), Keyword(id=1330225311276446677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, language=CN, orderNo=1, keyword=嵌合抗原受体T细胞(CAR-T)), Keyword(id=1330225311339361239, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, language=CN, orderNo=2, keyword=卫生技术评估), Keyword(id=1330225311398081496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, language=CN, orderNo=3, keyword=医保准入)], refs=[Reference(id=1330225311595213786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Gilead. Yescarta® is first CAR T-cell Therapy to report five-year survival data from pivotal study showing durable long-term survival in patients with refractory large B-cell lymphoma[EB/OL]. [2022-03-15]. https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/yescarta-is-first-car-t-cell-therapy-to-report-five-year-survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refract., articleTitle=null, refAbstract=null), Reference(id=1330225311666516955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study[J]. Blood, 2017, 130(16): 1800-1808., articleTitle=null, refAbstract=null), Reference(id=1330225311729431516, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Moreno-Cortes E, Forero-Forero JV, Lengerke-Diaz PA, et al. Chimeric antigen receptor T cell therapy in oncology - pipeline at a glance: analysis of the ClinicalTrials. gov database[J]. Crit Rev Oncol Hematol, 2021, 159: 103239., articleTitle=null, refAbstract=null), Reference(id=1330225311792346077, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Neelapu SS. Managing the toxicities of CAR T-cell therapy[J]. Hematol oncol, 2019, 37(suppl 1): 48-52., articleTitle=null, refAbstract=null), Reference(id=1330225313419736030, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries[J]. J Market Access Health Policy, 2020, 8(1): 1715536., articleTitle=null, refAbstract=null), Reference(id=1330225313495233503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Evans SR. Clinical trial structures[J]. J Experiment Stroke Translat Med, 2010, 3(1): 8-18., articleTitle=null, refAbstract=null), Reference(id=1330225313570730976, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase Ⅱ cancer clinical trials[J]. J Clin Oncol, 2010, 28(11): 1936-1941., articleTitle=null, refAbstract=null), Reference(id=1330225313658811361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=徐赫, 田磊, 孟蕊, 等. 不同类型研究设计在卫生决策中的应用情况[J]. 中国医院药学杂志, 2020, 40(18): 1905-1909., articleTitle=null, refAbstract=null), Reference(id=1330225313734308834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=丁锦希, 李伟. “守正创新, 为人民健康谋福祉”谈2021年国家医保目录调整工作的三大亮点[J]. 世界临床药物, 2022, 43(1): 1-4., articleTitle=null, refAbstract=null), Reference(id=1330225313809806307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=国家医疗保障局. 关于公示2021年国家医保药品目录调整通过初步形式审查药品及信息的公告[EB/OL]. [2022-03-10]. http://www.nhsa.gov.cn/art/2021/7/30/art_62_5678.html., articleTitle=null, refAbstract=null), Reference(id=1330225313860137956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=王春露, 吴妍, 许效, 等. 欧洲四国关于CAR-T细胞治疗的卫生技术评估经验及其对产品市场准入路径的影响[J]. 中国合理用药探索, 2021, 18(5): 1-12., articleTitle=null, refAbstract=null), Reference(id=1330225313927246821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=高强. 120万元一针抗癌药值不值[J]. 食品与健康, 2021, 33(12): 10-11., articleTitle=null, refAbstract=null), Reference(id=1330225313998549990, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=兴业证券. CAR-T行业深度报告: 细胞治疗, 七载归来方始坼[EB/OL]. [2022-03-15]. https://xueqiu.com/4396147139/189990378., articleTitle=null, refAbstract=null), Reference(id=1330225314065658855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=GILEAD. Yescarta® ZUMA-12 study demonstrates 78% complete response rate as part of first-line treatment in newly diagnosed high-risk large B-Cell lymphoma[EB/OL]. [2022-03-02]. https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/yescarta-zuma12-study-demonstrates-78-complete-response-rate-as-part-of-firstline-treatment-in-newly-diagnosed-highrisk-large-bcell-lymphoma., articleTitle=null, refAbstract=null), Reference(id=1330225314128573416, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=杨宏, 李皓静, 罗丹阳, 等. 肿瘤免疫治疗超进展的研究和展望[J]. 中南医学科学杂志, 2022, 50(2): 297-301., articleTitle=null, refAbstract=null), Reference(id=1330225314183099369, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=CADTH. Axicabtagene ciloleucel and tisagenlecleucel for diffuse large B-cell lymphoma[EB/OL]. [2022-03-10]. https://www.cadth.ca/axicabtagene-ciloleucel-and-tisagenlecleucel-diffuse-large-b-cell-lymphoma., articleTitle=null, refAbstract=null), Reference(id=1330225314241819626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies[EB/OL]. [2022-03-05]. https://www.nice.org.uk/guidance/ta559., articleTitle=null, refAbstract=null), Reference(id=1330225314300539883, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735., articleTitle=null, refAbstract=null), Reference(id=1330225314384425964, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=HAS. TECARTUS (cellules autologues CD3+ transduites anti-CD19)[EB/OL]. [2022-03-04]. https://www.has-sante.fr/jcms/p_3265892/fr/tecartus-cellules-autologues-cd3-transduites-anti-cd19., articleTitle=null, refAbstract=null), Reference(id=1330225314447340525, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head comparative studies: challenges and opportunities[J]. J Crohns Colitis, 2017, 11(suppl 2): S567-S575., articleTitle=null, refAbstract=null), Reference(id=1330225314510255086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research[J]. Value Health, 2012, 15(6): 940-947., articleTitle=null, refAbstract=null), Reference(id=1330225314585752559, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Ma Q, Zhang J, O'brien E, et al. Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia[J]. J Comp Eff Res, 2020, 9(12): 849-860., articleTitle=null, refAbstract=null), Reference(id=1330225314652861424, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-Cell therapy in multiply relapsed or refractory adult large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(24): 2105-2119., articleTitle=null, refAbstract=null), Reference(id=1330225314728358897, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Vitale C, Strati P. CAR T-cell therapy for B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences[J]. Front Oncol, 2020, 10: 849., articleTitle=null, refAbstract=null), Reference(id=1330225314791273458, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years[EB/OL]. [2022-03-04]. https://www.nice.org.uk/guidance/ta554., articleTitle=null, refAbstract=null), Reference(id=1330225314854188019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models[J]. Med Decis Making, 2019, 39(3): 294-298., articleTitle=null, refAbstract=null), Reference(id=1330225314921296884, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=李伟, 覃胡莉, 丁锦希, 等. CAR-T产品医保准入风险分担协议的国际经验及启示[J]. 中国药房, 2021, 32(24): 2957-2962., articleTitle=null, refAbstract=null), Reference(id=1330225314980017141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=HAS. YESCARTA (axicabtagene ciloleucel), CAR T anti-CD19[EB/OL]. [2022-03-05]. https://www.has-sante.fr/jcms/pprd_2982978/fr/yescarta-axicabtagene-ciloleucel-car-t-anti-cd19., articleTitle=null, refAbstract=null), Reference(id=1330225315038737398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=CADTH. Tisagenlecleucel for Acute Lymphoblastic Leukemia: Economic Review Report[EB/OL]. (2019-01-15) [2022-03-04]. https://www.cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-economic-report-pALL-jan2019.pdf., articleTitle=null, refAbstract=null), Reference(id=1330225315097457655, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=柳鹏程, 李灿, 杜怿, 等. 中国医保预算影响分析的研究范式[J]. 卫生经济研究, 2021, 38(1): 40-46., articleTitle=null, refAbstract=null), Reference(id=1330225315172955128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Heine R, Thielen FW, Koopmanschap M, et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future[J]. HemaSphere, 2021, 5(2): e524., articleTitle=null, refAbstract=null), Reference(id=1330225315261035513, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang XJ, Wang YH, Li SCT, et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective[J]. J Med Econ, 2021, 24(1): 637-653., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330225311494550489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, awardId=CPU2018GY4, language=CN, fundingSource=中国药科大学“双一流”学科创新团队建设项目(CPU2018GY4), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.04.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.04.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.04.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.04.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1649520000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
嵌合抗原受体T细胞产品卫生技术评估新思路
冯依曼 1 , 丁锦希 1, 2, * , 李佳明 1, 2 , 李伟 1, 2
世界临床药物 | 医药专论 2022,43(4): 377-385
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (4) : 377 -385
嵌合抗原受体T细胞产品卫生技术评估新思路
全屏
[Author(id=1330225310215287739, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225310299173821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310215287739, language=EN, stringName=Yiman FENG, firstName=Yiman, middleName=null, lastName=FENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310362088382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310215287739, language=CN, stringName=冯依曼, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国药科大学国际医药商学院,江苏 南京 211198, bio={"content":"

冯依曼,硕士研究生,研究方向:药物经济学和医保准入。

"}, bioImg=null, bioContent=

冯依曼,硕士研究生,研究方向:药物经济学和医保准入。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)])]), Author(id=1330225310433391553, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225310504694724, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310433391553, language=EN, stringName=Jinxi DING, firstName=Jinxi, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310571803589, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310433391553, language=CN, stringName=丁锦希, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.中国药科大学国际医药商学院,江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])]), Author(id=1330225310655689671, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225310718604234, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310655689671, language=EN, stringName=Jiaming LI, firstName=Jiaming, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310777324491, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310655689671, language=CN, stringName=李佳明, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国药科大学国际医药商学院,江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])]), Author(id=1330225310857016269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225310932513744, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310857016269, language=EN, stringName=Wei LI, firstName=Wei, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225310987039697, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, authorId=1330225310857016269, language=CN, stringName=李伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国药科大学国际医药商学院,江苏 南京 211198
2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225309888132020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=1., ext=[AuthorCompanyExt(id=1330225309900714933, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225309909103542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309888132020, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国药科大学国际医药商学院,江苏 南京 211198)]), AuthorCompany(id=1330225309976212407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, xref=2., ext=[AuthorCompanyExt(id=1330225310114624440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China), AuthorCompanyExt(id=1330225310135595961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225309212849073, companyId=1330225309976212407, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198)])])]
冯依曼1, 丁锦希1, 2, *, 李佳明1, 2, 李伟1, 2
作者信息
  • 1.中国药科大学国际医药商学院,江苏 南京 211198
  • 2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198
通讯作者:
丁锦希,教授,博士生导师,研究方向:医药政策法规、医药市场准入与药物经济学。
作者简介:

冯依曼,硕士研究生,研究方向:药物经济学和医保准入。

A new approach to chimeric antigen receptor T cell products health technology assessment
Yiman FENG1, Jinxi DING1, 2, *, Jiaming LI1, 2, Wei LI1, 2
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
出版时间: 2022-04-10 doi: 10.13683/j.wph.2022.04.005
文章导航
收藏切换

嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)是一种全新的肿瘤免疫治疗产品。针对CAR-T产品卫生技术评估面临的两个难点,即临床证据不足和治疗费用昂贵,该文在分析借鉴国际经验基础上,提出卫生技术评估的优化思路,包括优选参照方案、优化评估方案和精算预算影响,以期为CAR-T产品卫生技术评估提供新思路。

嵌合抗原受体T细胞(CAR-T)  /  卫生技术评估  /  医保准入

Chimeric antigen receptor T cell (CAR-T) is a novel cancer immunotherapy. In order to solve two major difficulties of CAR-T health technology assessment (insufficient clinical evidence and high treatment cost), this paper proposed optimization ideas for health technology assessment on the basis of analyzing and learning international experience, including optimizing the selection of reference, optimizing assessment scheme and calculating budget impact precisely.

chimeric antigen receptor T cell (CAR-T)  /  health technology assessment  /  medical insurance access
冯依曼, 丁锦希, 李佳明, 李伟. 嵌合抗原受体T细胞产品卫生技术评估新思路. 世界临床药物, 2022 , 43 (4) : 377 -385 . DOI: 10.13683/j.wph.2022.04.005
Yiman FENG, Jinxi DING, Jiaming LI, Wei LI. A new approach to chimeric antigen receptor T cell products health technology assessment[J]. World Clinical Drug, 2022 , 43 (4) : 377 -385 . DOI: 10.13683/j.wph.2022.04.005
  • 中国药科大学“双一流”学科创新团队建设项目(CPU2018GY4)
参考文献 引证文献
排序方式:
[1]
Gilead. Yescarta® is first CAR T-cell Therapy to report five-year survival data from pivotal study showing durable long-term survival in patients with refractory large B-cell lymphoma[EB/OL]. [2022-03-15]. https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/yescarta-is-first-car-t-cell-therapy-to-report-five-year-survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refract.
[2]
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study[J]. Blood, 2017, 130(16): 1800-1808.
[3]
Moreno-Cortes E, Forero-Forero JV, Lengerke-Diaz PA, et al. Chimeric antigen receptor T cell therapy in oncology - pipeline at a glance: analysis of the ClinicalTrials. gov database[J]. Crit Rev Oncol Hematol, 2021, 159: 103239.
[4]
Neelapu SS. Managing the toxicities of CAR T-cell therapy[J]. Hematol oncol, 2019, 37(suppl 1): 48-52.
[5]
Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries[J]. J Market Access Health Policy, 2020, 8(1): 1715536.
[6]
Evans SR. Clinical trial structures[J]. J Experiment Stroke Translat Med, 2010, 3(1): 8-18.
[7]
Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase Ⅱ cancer clinical trials[J]. J Clin Oncol, 2010, 28(11): 1936-1941.
[8]
徐赫, 田磊, 孟蕊, 等. 不同类型研究设计在卫生决策中的应用情况[J]. 中国医院药学杂志, 2020, 40(18): 1905-1909.
[9]
丁锦希, 李伟. “守正创新, 为人民健康谋福祉”谈2021年国家医保目录调整工作的三大亮点[J]. 世界临床药物, 2022, 43(1): 1-4.
[10]
国家医疗保障局. 关于公示2021年国家医保药品目录调整通过初步形式审查药品及信息的公告[EB/OL]. [2022-03-10]. http://www.nhsa.gov.cn/art/2021/7/30/art_62_5678.html.
[11]
王春露, 吴妍, 许效, 等. 欧洲四国关于CAR-T细胞治疗的卫生技术评估经验及其对产品市场准入路径的影响[J]. 中国合理用药探索, 2021, 18(5): 1-12.
[12]
高强. 120万元一针抗癌药值不值[J]. 食品与健康, 2021, 33(12): 10-11.
[13]
兴业证券. CAR-T行业深度报告: 细胞治疗, 七载归来方始坼[EB/OL]. [2022-03-15]. https://xueqiu.com/4396147139/189990378.
[14]
GILEAD. Yescarta® ZUMA-12 study demonstrates 78% complete response rate as part of first-line treatment in newly diagnosed high-risk large B-Cell lymphoma[EB/OL]. [2022-03-02]. https://www.gilead.com/news-and-press/press-room/press-releases/2021/12/yescarta-zuma12-study-demonstrates-78-complete-response-rate-as-part-of-firstline-treatment-in-newly-diagnosed-highrisk-large-bcell-lymphoma.
[15]
杨宏, 李皓静, 罗丹阳, 等. 肿瘤免疫治疗超进展的研究和展望[J]. 中南医学科学杂志, 2022, 50(2): 297-301.
[16]
CADTH. Axicabtagene ciloleucel and tisagenlecleucel for diffuse large B-cell lymphoma[EB/OL]. [2022-03-10]. https://www.cadth.ca/axicabtagene-ciloleucel-and-tisagenlecleucel-diffuse-large-b-cell-lymphoma.
[17]
NICE. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies[EB/OL]. [2022-03-05]. https://www.nice.org.uk/guidance/ta559.
[18]
中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735.
[19]
HAS. TECARTUS (cellules autologues CD3+ transduites anti-CD19)[EB/OL]. [2022-03-04]. https://www.has-sante.fr/jcms/p_3265892/fr/tecartus-cellules-autologues-cd3-transduites-anti-cd19.
[20]
Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head comparative studies: challenges and opportunities[J]. J Crohns Colitis, 2017, 11(suppl 2): S567-S575.
[21]
Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research[J]. Value Health, 2012, 15(6): 940-947.
[22]
Ma Q, Zhang J, O'brien E, et al. Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia[J]. J Comp Eff Res, 2020, 9(12): 849-860.
[23]
Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-Cell therapy in multiply relapsed or refractory adult large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(24): 2105-2119.
[24]
Vitale C, Strati P. CAR T-cell therapy for B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences[J]. Front Oncol, 2020, 10: 849.
[25]
NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years[EB/OL]. [2022-03-04]. https://www.nice.org.uk/guidance/ta554.
[26]
Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models[J]. Med Decis Making, 2019, 39(3): 294-298.
[27]
李伟, 覃胡莉, 丁锦希, 等. CAR-T产品医保准入风险分担协议的国际经验及启示[J]. 中国药房, 2021, 32(24): 2957-2962.
[28]
HAS. YESCARTA (axicabtagene ciloleucel), CAR T anti-CD19[EB/OL]. [2022-03-05]. https://www.has-sante.fr/jcms/pprd_2982978/fr/yescarta-axicabtagene-ciloleucel-car-t-anti-cd19.
[29]
CADTH. Tisagenlecleucel for Acute Lymphoblastic Leukemia: Economic Review Report[EB/OL]. (2019-01-15) [2022-03-04]. https://www.cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-economic-report-pALL-jan2019.pdf.
[30]
柳鹏程, 李灿, 杜怿, 等. 中国医保预算影响分析的研究范式[J]. 卫生经济研究, 2021, 38(1): 40-46.
[31]
Heine R, Thielen FW, Koopmanschap M, et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future[J]. HemaSphere, 2021, 5(2): e524.
[32]
Wang XJ, Wang YH, Li SCT, et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective[J]. J Med Econ, 2021, 24(1): 637-653.
2022年第43卷第4期
13
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.04.005
  • 接收时间:2022-01-28
  • 首发时间:2026-11-19
  • 出版时间:2022-04-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-01-28
基金
中国药科大学“双一流”学科创新团队建设项目(CPU2018GY4)
作者信息
    1.中国药科大学国际医药商学院,江苏 南京 211198
    2.中国药科大学医药市场准入政策研究中心,江苏 南京 211198

通讯作者:

丁锦希,教授,博士生导师,研究方向:医药政策法规、医药市场准入与药物经济学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.04.005
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏